Ian B. Li
Adele C. Oliva
Adele Oliva has decades of finance and healthcare experience, including 20 years in private equity focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.
Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors, and top women in venture capital. In 2016, Adele was recognized by the Philadelphia Business Journal as part of the Power 76 list of the region’s most influential people. Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.
Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Encore Dermatology, Genoptix, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.
Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing. While at Palm, Michael led investments in Enigma Diagnostics, Axcentria Pharmaceuticals, and JDS Therapeutics. He currently serves on the boards of Interphase Medical Equipment and JDS Therapeutics.
Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.
Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.
Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director.
Matthew has over a decade of growth stage investing experience with a focus on the specialty pharmaceutical and medical technology sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners. Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financings over the course of his career.
Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.
Edward Chan joined 1315 Capital in 2016 after spending 5 years at NaviMed Capital, most recently as a Vice President. Prior to joining NaviMed Capital, Edward was part of the healthcare investment team at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced commercial and growth stage healthcare deals worldwide, performed research on various market sectors, and supported portfolio companies.
Edward also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company.
Prior to 1315 Capital, Edward was actively involved, at both NaviMed and Siemens Ventures, in the following investments: CenterPointe Behavioral Health System, Lucent Health Solutions, China Diagnostics Medical Corporation (acquired by Actis Capital), BioImagene (acquired by Roche), RadPharm (acquired by JLL Partners), U-Systems (acquired by GE), MD Datacor (acquired by Noridian Mutual Insurance), Zonare (acquired by Mindray), and Cylex (acquired by Viracor-IBT). He is currently a Genoptix board observer.
Edward received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania, where he was President of the Healthcare Club.
Ian B. Li
Ian Li joined 1315 Capital in 2015, after spending 4 years as a healthcare management and strategy consultant, most recently at Capgemini Consulting. Ian has worked with commercial executives from top pharmaceutical companies on implementing large scale strategic initiatives, with projects spanning market access, product launch, healthcare reform readiness, and engagement of integrated health network (IHN) customers. Prior to consulting, Ian also had experience working at Stryker Orthopaedics in the quality engineering department.
Ian received a BSc in Biomedical Engineering from Duke University, with a minor in Economics.
Craig Matturro joined 1315 Capital in 2016 after 2 years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.
Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.
Operating Team Member
Tim Einwechter is co-founder and Chief Financial Officer of Innovative Health, a medical device reprocessing company focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, he was co-founder and Chief Financial Officer for Intralign. Tim was also Chief Financial Officer of Alliance Medical, and later Ascent Healthcare Solutions (acquired by Stryker for $525 million). Prior to joining Alliance Medical, Tim was Chief Operating Officer of Healthworks Managed Care Services, a private company engaged in the provision of rehabilitation services. He also spent time as Chief Financial Officer of Dynacare Health Services, a publicly traded health services company engaged in the business of providing home healthcare and laboratory diagnostic services, and before that tenured as a Vice President of Versa-Care, a company engaged in the provision of accommodation for senior citizens.
Tim was named Arizona’s 2010 Private Company CFO of the Year by the Financial Executives Institute.
Tim received an Honors BA in Business Administration from Wilfrid Laurier University and is a Chartered Accountant.
Operating Team Member
Rick Ferreira is a serial entrepreneur and currently President & CEO of Innovative Health, a medical device reprocessing company he co-founded focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, Rick was President & CEO of Intralign, a company he co-founded to help hospitals and surgeons reduce costs and improve efficiencies around joint replacement surgery. Prior to Intralign, Rick founded Alliance Medical in 1997, the first major medical device reprocessing company. Alliance Medical merged with Vanguard Medical Concepts in 2005 to become Ascent Healthcare Solutions (acquired by Stryker for $525 million).
Rick started his first company, International Managed Healthcare, a Canadian company engaged in the provision of rehabilitation services, in 1990. The company was sold to Liberty Mutual Insurance in 1994. Rick began his career with the Royal Bank of Canada.
Rick received a BA in Business Administration from the University of Toronto.
Operating Team Member
Antony Koblish is a medical device entrepreneur with 25 years of experience in healthcare. Antony is co-founder and President & CEO of TELA Bio, a biosurgical reconstruction company based in Malvern, Pennsylvania. Prior to founding TELA Bio, Antony was President and CEO of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as CEO of Orthovita from 2002 to 2011, Antony created significant company value, growing valuation from $30 million to a $316 million sale to Stryker Corporation in May 2011. Antony is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical & manufacturing quality.
Antony is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, a surgical oncology company.
Antony received a BSc in Mechanical Engineering from Worcester Polytechnic Institute, and an MS in Mechanical Engineering & Applied Mechanics from the University of Pennsylvania.
Operating Team Member
Greg Stokes is Chief Executive Officer of NovaSom, and has 25 years of pharmaceutical and medical device experience, having worked in sales, marketing, and business development. Prior to NovaSom, he co-founded and served as Executive Vice President of Business Development at Oceana Therapeutics (acquired by Salix for $300 million). Previous positions include co-founder, President and Chief Operating Officer of Esprit Pharma, Inc. (acquired by Allergan for $360 million), Vice President of Corporate Development for ESP Pharma (acquired by Protein Design Labs for $500 million), and Director of Business Development with Shire.
Greg received a BA from University of Pennsylvania, JD from Rutgers University and MBA from Rutgers University.
Operating Team Member
Paul Touhey is Executive Chairman of Invisible Sentinel, Inc., a molecular diagnostics company located in Philadelphia, PA. He is the former President / CEO and member of the Board of Directors of Fujirebio Diagnostics, Inc. (FDI), a premier cancer diagnostics company. Paul has more than 25 years of industry experience.
Paul joined FDI (formerly Centocor Diagnostics) in 1985, where he held a variety of positions, including Senior Vice President of Operations. Prior to FDI and Centocor, Paul worked for Johnson & Johnson in a variety of positions with increasing levels of responsibility and management.
Paul is the past Chairman of the Board of the Medical Device Manufacturers Association (MDMA), a national trade association representing the entrepreneurial sector of the medical device industry in the United States. He also serves on the Board of the University City Science Center. Paul established the Companies of Caring campaign with the Community Volunteers in Medicine, a Chester County charity focusing on providing medical care to the uninsured.
Paul serves as Chairman of TELA Bio and on the Board of Directors for Genoptix and Onkos Surgical, and previously served on the Board of Directors of Orthovita, Inc., a publicly traded orthobiologics company (acquired by Stryker in 2011).
Paul received a BA in Political Science from Temple University.
Chief Financial Officer
Brian Schwenk joined 1315 Capital in 2014, and has 14 years of experience in private equity and public accounting. Since 2012, Brian has worked with Adele Oliva at Quaker Partners as Chief Financial Officer. His roles at 1315 Capital include oversight of accounting, treasury, financial reporting, and performance analysis as well as human resources, investor relations, information technology, risk management, and compliance.
Brian also spent nearly 7 years at an affiliate of Quaker, Independence Capital Partners, most recently as Senior Controller. Earlier in his career, Brian worked for American Express Tax & Business Services, Stout Causey Consulting, and Arthur F. Bell, Jr. & Associates as an audit associate.
Brian received a BA in management with a concentration in Accounting from Gettysburg College and an MBA with a concentration in Accounting from Loyola College in Maryland.
Lisa Chirre joined 1315 Capital in 2016 as an Executive Assistant after nearly 20 years in the insurance and legal industries. Most recently, Lisa was part of the Information Technology Department of the ACE Group, where she provided support to the EVP, Global Chief Information Officer. Prior to ACE, Lisa worked at Ballard Spahr, where she supported the Chief Technology Officer. In addition, Lisa is fluent in Spanish.